FeesSafety
Pluang+

Lawsuit probes Iovance after lung cancer trial data revision causes 35% stock drop

Market News
18 Nov 2026, 00:33 WIB
GlobeNewsWire
View Source
Bearish
Lawsuit probes Iovance after lung cancer trial data revision causes 35% stock drop

Pomerantz LLP is investigating Iovance Biotherapeutics for potential securities fraud following a revision in its lung cancer trial results. Initially reported as "Positive," the Phase 2 trial data was later described as "Consistent with Previously Reported Results," revealing a subgroup response rate lower than standard treatment. This led to a 35.45% drop in Iovance's stock price. The investigation will determine if the company or its executives misled investors, impacting shareholder value.

Iovance Biotherapeutics (IOVA) is trading at USD 7.47 on Pluang as of Nov 18, 2026 05:31 WIB, down 1.06% for the day. This price is significantly below its 52-week high of USD 14.86 but well above the 52-week low of USD 2.13, indicating a wide range of volatility over the past year. The typical hold time for IOVA on Pluang is 8 days, reflecting relatively short-term investor interest.

More News (IOVA)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App